Views & Analysis
As cancer treatments evolve, so must investment mechanisms
Last month’s American Society of Clinical Oncology (ASCO) meeting kicked off with a presentation from Professor Ruth Plummer, a medical oncologist from Newcastle in the UK who, in 2003, was